Allison Navis1, Ifunanya Dallah2, Charles Mabeta3, Kalo Musukuma4, Omar K Siddiqi5,6,7, Christopher M Bositis8, Igor J Koralnik9, Harris A Gelbard10, William H Theodore11, Jason F Okulicz12, Brent A Johnson13, Izukanji Sikazwe14, David R Bearden2, Gretchen L Birbeck2,3,4. 1. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2. Department of Neurology, University of Rochester, Rochester, NY, USA. 3. Chikankata Epilepsy Care Team, Mazabuka, Zambia. 4. University Teaching Hospitals Children's Hospital, Lusaka, Zambia. 5. Global Neurology Program, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 6. Department of Internal Medicine, Center for Vaccines and Virology Research, Beth Israel Deaconess Medical Center, Boston, MA, USA. 7. Department of Internal Medicine, University of Zambia School of Medicine, Lusaka, Zambia. 8. Greater Lawrence Family Health Center, Lawrence, MA, USA. 9. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 10. Departments of Neurology, Pediatrics, Neuroscience and Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA. 11. National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. 12. Infectious Disease Service, Brooke Army Medical Center, Joint Base San Antonio-Ft Sam Houston, Houston, TX, USA. 13. Department of Biostatistics, Center for AIDS Research, University of Rochester, Rochester, NY, USA. 14. Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia.
Abstract
OBJECTIVE: Interactions between enzyme-inducing anti-seizure medications (EI-ASMs) and antiretroviral drugs (ARVs) can lead to decreased ARV levels and may increase the likelihood of viral resistance. We conducted a study to determine if co-usage of ARVs and EI-ASMs is associated with ARV-resistant human immunodeficiency virus (HIV) among people living with HIV in Zambia. METHODS: Eligible participants were ≥18 years of age and concurrently taking ASMs and ARVs for at least 1 month of the prior 6-month period. Data were obtained regarding medication and HIV history. CD4 counts, plasma viral loads (pVLs), and HIV genotype and resistance profile in participants with a pVL >1000 copies/mL were obtained. Pearson's test of independence was used to determine whether treatment with EI-ASM was associated with pVL >1000/mL copies. RESULTS: Of 50 participants, 41 (82%) were taking carbamazepine (37 on monotherapy), and all had stable regimens in the prior 6 months. Among the 13 ARV regimens used, 68% had a tenofovir/lamivudine backbone. The majority (94%) were on a stable ARV regimen for >6 months. Median CD4 nadir was 205 cells/mm3 (interquartile range [IQR] 88-389), and 60% of participants had commenced ARV treatment before advanced disease occurred. Mean CD4 count at enrollment was 464 cells/mm3 (SD 226.3). Seven participants (14%) had a CD4 count <200 cells/mm3 . Four (8%) had a pVL >1000 copies/mL; all were on carbamazepine. Three participants with elevated pVL had a CD4 count <200 cells/mm3 . None had documented adherence concerns by providers; however, two had events concerning for clinical failure. HIV genotype testing showed mutations in three participants. Carbamazepine was not found to correlate with elevated pVL (P = .58). SIGNIFICANCE: EI-ASMs are commonly used in sub-Saharan Africa. Despite concurrent use of EI-ASMs and ARVs, the majority of participants showed CD4 counts >200 cells/mm3 and were virally suppressed. Carbamazepine was not associated with an increased risk of virological failure or ARV-resistant HIV.
OBJECTIVE: Interactions between enzyme-inducing anti-seizure medications (EI-ASMs) and antiretroviral drugs (ARVs) can lead to decreased ARV levels and may increase the likelihood of viral resistance. We conducted a study to determine if co-usage of ARVs and EI-ASMs is associated with ARV-resistant human immunodeficiency virus (HIV) among people living with HIV in Zambia. METHODS: Eligible participants were ≥18 years of age and concurrently taking ASMs and ARVs for at least 1 month of the prior 6-month period. Data were obtained regarding medication and HIV history. CD4 counts, plasma viral loads (pVLs), and HIV genotype and resistance profile in participants with a pVL >1000 copies/mL were obtained. Pearson's test of independence was used to determine whether treatment with EI-ASM was associated with pVL >1000/mL copies. RESULTS: Of 50 participants, 41 (82%) were taking carbamazepine (37 on monotherapy), and all had stable regimens in the prior 6 months. Among the 13 ARV regimens used, 68% had a tenofovir/lamivudine backbone. The majority (94%) were on a stable ARV regimen for >6 months. Median CD4 nadir was 205 cells/mm3 (interquartile range [IQR] 88-389), and 60% of participants had commenced ARV treatment before advanced disease occurred. Mean CD4 count at enrollment was 464 cells/mm3 (SD 226.3). Seven participants (14%) had a CD4 count <200 cells/mm3 . Four (8%) had a pVL >1000 copies/mL; all were on carbamazepine. Three participants with elevated pVL had a CD4 count <200 cells/mm3 . None had documented adherence concerns by providers; however, two had events concerning for clinical failure. HIV genotype testing showed mutations in three participants. Carbamazepine was not found to correlate with elevated pVL (P = .58). SIGNIFICANCE: EI-ASMs are commonly used in sub-Saharan Africa. Despite concurrent use of EI-ASMs and ARVs, the majority of participants showed CD4 counts >200 cells/mm3 and were virally suppressed. Carbamazepine was not associated with an increased risk of virological failure or ARV-resistant HIV.
Authors: Nicolas A Margot; Erica Isaacson; Ian McGowan; Andrew K Cheng; Robert T Schooley; Michael D Miller Journal: AIDS Date: 2002-06-14 Impact factor: 4.177
Authors: I Sikazwe; M A Elafros; C M Bositis; O K Siddiqi; I J Koralnik; L Kalungwana; W H Theodore; J F Okulicz; M J Potchen; G L Birbeck Journal: HIV Med Date: 2015-07-22 Impact factor: 3.180
Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2014 Jun-Jul
Authors: Matthew P Fox; Gilles Van Cutsem; Janet Giddy; Mhairi Maskew; Olivia Keiser; Hans Prozesky; Robin Wood; Miguel A Hernán; Jonathan A C Sterne; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731